ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Radionuclide Drug Conjugates (RDC) Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-30H14685
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Radionuclide Drug Conjugates RDC Market Research Report 2023
BUY CHAPTERS

Global Radionuclide Drug Conjugates (RDC) Market Research Report 2025

Code: QYRE-Auto-30H14685
Report
May 2025
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
POINT Biopharma
Telix
ITM
Bayer
Novartis
Lantheus
Curium Pharma
Grand Pharma
Hengrui Medicine
Yunnan Baiyao Group
Uihc Pet Imaging
BoomRay Pharmaceuticals
SmartNuclide Biopharma
Sinotau
Hexin Pharmaceutical
Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.

Radionuclide Drug Conjugates (RDC) Market

The global market for Radionuclide Drug Conjugates (RDC) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.
According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.
At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.
According to different targeting ligands, RDC can be subdivided into: antibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).
According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor ); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.
This report aims to provide a comprehensive presentation of the global market for Radionuclide Drug Conjugates (RDC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radionuclide Drug Conjugates (RDC).
The Radionuclide Drug Conjugates (RDC) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Radionuclide Drug Conjugates (RDC) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radionuclide Drug Conjugates (RDC) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Radionuclide Drug Conjugates (RDC) Market Report

Report Metric Details
Report Name Radionuclide Drug Conjugates (RDC) Market
Segment by Type
Segment by Application
  • Neuroendocrine Tumors
  • Prostate Cancer
  • Renal Cell Carcinoma
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Uihc Pet Imaging, Grand Pharma, BoomRay Pharmaceuticals, SmartNuclide Biopharma, Hengrui Medicine, Yunnan Baiyao Group, Sinotau, Hexin Pharmaceutical, Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Radionuclide Drug Conjugates (RDC) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Radionuclide Drug Conjugates (RDC) Market report?

Ans: The main players in the Radionuclide Drug Conjugates (RDC) Market are POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Uihc Pet Imaging, Grand Pharma, BoomRay Pharmaceuticals, SmartNuclide Biopharma, Hengrui Medicine, Yunnan Baiyao Group, Sinotau, Hexin Pharmaceutical, Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.

What are the Application segmentation covered in the Radionuclide Drug Conjugates (RDC) Market report?

Ans: The Applications covered in the Radionuclide Drug Conjugates (RDC) Market report are Neuroendocrine Tumors, Prostate Cancer, Renal Cell Carcinoma

What are the Type segmentation covered in the Radionuclide Drug Conjugates (RDC) Market report?

Ans: The Types covered in the Radionuclide Drug Conjugates (RDC) Market report are Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)

Recommended Reports

Radionuclide-Based Therapies

Nuclear Medicine Solutions

Radiopharmaceutical Products

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antibody Radionuclide Conjugates (ARC)
1.2.3 Peptide Radionuclide Conjugates (PRC)
1.2.4 Small Molecular Radionuclide Conjugates (SMRC)
1.3 Market by Application
1.3.1 Global Radionuclide Drug Conjugates (RDC) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Neuroendocrine Tumors
1.3.3 Prostate Cancer
1.3.4 Renal Cell Carcinoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radionuclide Drug Conjugates (RDC) Market Perspective (2020-2031)
2.2 Global Radionuclide Drug Conjugates (RDC) Growth Trends by Region
2.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Radionuclide Drug Conjugates (RDC) Historic Market Size by Region (2020-2025)
2.2.3 Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2026-2031)
2.3 Radionuclide Drug Conjugates (RDC) Market Dynamics
2.3.1 Radionuclide Drug Conjugates (RDC) Industry Trends
2.3.2 Radionuclide Drug Conjugates (RDC) Market Drivers
2.3.3 Radionuclide Drug Conjugates (RDC) Market Challenges
2.3.4 Radionuclide Drug Conjugates (RDC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radionuclide Drug Conjugates (RDC) Players by Revenue
3.1.1 Global Top Radionuclide Drug Conjugates (RDC) Players by Revenue (2020-2025)
3.1.2 Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Players (2020-2025)
3.2 Global Radionuclide Drug Conjugates (RDC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Radionuclide Drug Conjugates (RDC) Revenue
3.4 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio
3.4.1 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radionuclide Drug Conjugates (RDC) Revenue in 2024
3.5 Global Key Players of Radionuclide Drug Conjugates (RDC) Head office and Area Served
3.6 Global Key Players of Radionuclide Drug Conjugates (RDC), Product and Application
3.7 Global Key Players of Radionuclide Drug Conjugates (RDC), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Radionuclide Drug Conjugates (RDC) Breakdown Data by Type
4.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Type (2020-2025)
4.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Type (2026-2031)
5 Radionuclide Drug Conjugates (RDC) Breakdown Data by Application
5.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Application (2020-2025)
5.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)
6.2 North America Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025)
6.4 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)
7.2 Europe Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025)
7.4 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)
8.2 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2020-2025)
8.4 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)
9.2 Latin America Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025)
9.4 Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)
10.2 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025)
10.4 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 POINT Biopharma
11.1.1 POINT Biopharma Company Details
11.1.2 POINT Biopharma Business Overview
11.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Introduction
11.1.4 POINT Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.1.5 POINT Biopharma Recent Development
11.2 Telix
11.2.1 Telix Company Details
11.2.2 Telix Business Overview
11.2.3 Telix Radionuclide Drug Conjugates (RDC) Introduction
11.2.4 Telix Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.2.5 Telix Recent Development
11.3 ITM AG
11.3.1 ITM AG Company Details
11.3.2 ITM AG Business Overview
11.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Introduction
11.3.4 ITM AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.3.5 ITM AG Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Introduction
11.4.4 Bayer AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.4.5 Bayer AG Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Radionuclide Drug Conjugates (RDC) Introduction
11.5.4 Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Lantheus
11.6.1 Lantheus Company Details
11.6.2 Lantheus Business Overview
11.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Introduction
11.6.4 Lantheus Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.6.5 Lantheus Recent Development
11.7 Curium Pharma
11.7.1 Curium Pharma Company Details
11.7.2 Curium Pharma Business Overview
11.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Introduction
11.7.4 Curium Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.7.5 Curium Pharma Recent Development
11.8 Uihc Pet Imaging
11.8.1 Uihc Pet Imaging Company Details
11.8.2 Uihc Pet Imaging Business Overview
11.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Introduction
11.8.4 Uihc Pet Imaging Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.8.5 Uihc Pet Imaging Recent Development
11.9 Grand Pharma
11.9.1 Grand Pharma Company Details
11.9.2 Grand Pharma Business Overview
11.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Introduction
11.9.4 Grand Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.9.5 Grand Pharma Recent Development
11.10 BoomRay Pharmaceuticals
11.10.1 BoomRay Pharmaceuticals Company Details
11.10.2 BoomRay Pharmaceuticals Business Overview
11.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Introduction
11.10.4 BoomRay Pharmaceuticals Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.10.5 BoomRay Pharmaceuticals Recent Development
11.11 SmartNuclide Biopharma
11.11.1 SmartNuclide Biopharma Company Details
11.11.2 SmartNuclide Biopharma Business Overview
11.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Introduction
11.11.4 SmartNuclide Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.11.5 SmartNuclide Biopharma Recent Development
11.12 Hengrui Medicine
11.12.1 Hengrui Medicine Company Details
11.12.2 Hengrui Medicine Business Overview
11.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Introduction
11.12.4 Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.12.5 Hengrui Medicine Recent Development
11.13 Yunnan Baiyao Group
11.13.1 Yunnan Baiyao Group Company Details
11.13.2 Yunnan Baiyao Group Business Overview
11.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Introduction
11.13.4 Yunnan Baiyao Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.13.5 Yunnan Baiyao Group Recent Development
11.14 Sinotau
11.14.1 Sinotau Company Details
11.14.2 Sinotau Business Overview
11.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Introduction
11.14.4 Sinotau Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.14.5 Sinotau Recent Development
11.15 Hexin Pharmaceutical
11.15.1 Hexin Pharmaceutical Company Details
11.15.2 Hexin Pharmaceutical Business Overview
11.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Introduction
11.15.4 Hexin Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.15.5 Hexin Pharmaceutical Recent Development
11.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
11.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Details
11.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Business Overview
11.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Introduction
11.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
11.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
POINT Biopharma
Telix
ITM
Bayer
Novartis
Lantheus
Curium Pharma
Grand Pharma
Hengrui Medicine
Yunnan Baiyao Group
Uihc Pet Imaging
BoomRay Pharmaceuticals
SmartNuclide Biopharma
Sinotau
Hexin Pharmaceutical
Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
List of Tables
 Table 1. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Antibody Radionuclide Conjugates (ARC)
 Table 3. Key Players of Peptide Radionuclide Conjugates (PRC)
 Table 4. Key Players of Small Molecular Radionuclide Conjugates (SMRC)
 Table 5. Global Radionuclide Drug Conjugates (RDC) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Radionuclide Drug Conjugates (RDC) Market Share by Region (2020-2025)
 Table 9. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Radionuclide Drug Conjugates (RDC) Market Share by Region (2026-2031)
 Table 11. Radionuclide Drug Conjugates (RDC) Market Trends
 Table 12. Radionuclide Drug Conjugates (RDC) Market Drivers
 Table 13. Radionuclide Drug Conjugates (RDC) Market Challenges
 Table 14. Radionuclide Drug Conjugates (RDC) Market Restraints
 Table 15. Global Radionuclide Drug Conjugates (RDC) Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Radionuclide Drug Conjugates (RDC) Market Share by Players (2020-2025)
 Table 17. Global Top Radionuclide Drug Conjugates (RDC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide Drug Conjugates (RDC) as of 2024)
 Table 18. Ranking of Global Top Radionuclide Drug Conjugates (RDC) Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Radionuclide Drug Conjugates (RDC) Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Radionuclide Drug Conjugates (RDC), Headquarters and Area Served
 Table 21. Global Key Players of Radionuclide Drug Conjugates (RDC), Product and Application
 Table 22. Global Key Players of Radionuclide Drug Conjugates (RDC), Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Radionuclide Drug Conjugates (RDC) Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Type (2020-2025)
 Table 26. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Type (2026-2031)
 Table 28. Global Radionuclide Drug Conjugates (RDC) Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Application (2020-2025)
 Table 30. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Application (2026-2031)
 Table 32. North America Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031) & (US$ Million)
 Table 47. POINT Biopharma Company Details
 Table 48. POINT Biopharma Business Overview
 Table 49. POINT Biopharma Radionuclide Drug Conjugates (RDC) Product
 Table 50. POINT Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 51. POINT Biopharma Recent Development
 Table 52. Telix Company Details
 Table 53. Telix Business Overview
 Table 54. Telix Radionuclide Drug Conjugates (RDC) Product
 Table 55. Telix Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 56. Telix Recent Development
 Table 57. ITM AG Company Details
 Table 58. ITM AG Business Overview
 Table 59. ITM AG Radionuclide Drug Conjugates (RDC) Product
 Table 60. ITM AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 61. ITM AG Recent Development
 Table 62. Bayer AG Company Details
 Table 63. Bayer AG Business Overview
 Table 64. Bayer AG Radionuclide Drug Conjugates (RDC) Product
 Table 65. Bayer AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 66. Bayer AG Recent Development
 Table 67. Novartis Company Details
 Table 68. Novartis Business Overview
 Table 69. Novartis Radionuclide Drug Conjugates (RDC) Product
 Table 70. Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 71. Novartis Recent Development
 Table 72. Lantheus Company Details
 Table 73. Lantheus Business Overview
 Table 74. Lantheus Radionuclide Drug Conjugates (RDC) Product
 Table 75. Lantheus Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 76. Lantheus Recent Development
 Table 77. Curium Pharma Company Details
 Table 78. Curium Pharma Business Overview
 Table 79. Curium Pharma Radionuclide Drug Conjugates (RDC) Product
 Table 80. Curium Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 81. Curium Pharma Recent Development
 Table 82. Uihc Pet Imaging Company Details
 Table 83. Uihc Pet Imaging Business Overview
 Table 84. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product
 Table 85. Uihc Pet Imaging Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 86. Uihc Pet Imaging Recent Development
 Table 87. Grand Pharma Company Details
 Table 88. Grand Pharma Business Overview
 Table 89. Grand Pharma Radionuclide Drug Conjugates (RDC) Product
 Table 90. Grand Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 91. Grand Pharma Recent Development
 Table 92. BoomRay Pharmaceuticals Company Details
 Table 93. BoomRay Pharmaceuticals Business Overview
 Table 94. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product
 Table 95. BoomRay Pharmaceuticals Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 96. BoomRay Pharmaceuticals Recent Development
 Table 97. SmartNuclide Biopharma Company Details
 Table 98. SmartNuclide Biopharma Business Overview
 Table 99. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product
 Table 100. SmartNuclide Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 101. SmartNuclide Biopharma Recent Development
 Table 102. Hengrui Medicine Company Details
 Table 103. Hengrui Medicine Business Overview
 Table 104. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product
 Table 105. Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 106. Hengrui Medicine Recent Development
 Table 107. Yunnan Baiyao Group Company Details
 Table 108. Yunnan Baiyao Group Business Overview
 Table 109. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product
 Table 110. Yunnan Baiyao Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 111. Yunnan Baiyao Group Recent Development
 Table 112. Sinotau Company Details
 Table 113. Sinotau Business Overview
 Table 114. Sinotau Radionuclide Drug Conjugates (RDC) Product
 Table 115. Sinotau Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 116. Sinotau Recent Development
 Table 117. Hexin Pharmaceutical Company Details
 Table 118. Hexin Pharmaceutical Business Overview
 Table 119. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product
 Table 120. Hexin Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 121. Hexin Pharmaceutical Recent Development
 Table 122. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Details
 Table 123. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Business Overview
 Table 124. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product
 Table 125. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)
 Table 126. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Development
 Table 127. Research Programs/Design for This Report
 Table 128. Key Data Information from Secondary Sources
 Table 129. Key Data Information from Primary Sources
 Table 130. Authors List of This Report


List of Figures
 Figure 1. Radionuclide Drug Conjugates (RDC) Picture
 Figure 2. Global Radionuclide Drug Conjugates (RDC) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Radionuclide Drug Conjugates (RDC) Market Share by Type: 2024 VS 2031
 Figure 4. Antibody Radionuclide Conjugates (ARC) Features
 Figure 5. Peptide Radionuclide Conjugates (PRC) Features
 Figure 6. Small Molecular Radionuclide Conjugates (SMRC) Features
 Figure 7. Global Radionuclide Drug Conjugates (RDC) Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Radionuclide Drug Conjugates (RDC) Market Share by Application: 2024 VS 2031
 Figure 9. Neuroendocrine Tumors Case Studies
 Figure 10. Prostate Cancer Case Studies
 Figure 11. Renal Cell Carcinoma Case Studies
 Figure 12. Radionuclide Drug Conjugates (RDC) Report Years Considered
 Figure 13. Global Radionuclide Drug Conjugates (RDC) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Radionuclide Drug Conjugates (RDC) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Radionuclide Drug Conjugates (RDC) Market Share by Region: 2024 VS 2031
 Figure 16. Global Radionuclide Drug Conjugates (RDC) Market Share by Players in 2024
 Figure 17. Global Top Radionuclide Drug Conjugates (RDC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide Drug Conjugates (RDC) as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Radionuclide Drug Conjugates (RDC) Revenue in 2024
 Figure 19. North America Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Radionuclide Drug Conjugates (RDC) Market Share by Country (2020-2031)
 Figure 21. United States Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Radionuclide Drug Conjugates (RDC) Market Share by Country (2020-2031)
 Figure 25. Germany Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Share by Region (2020-2031)
 Figure 33. China Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Radionuclide Drug Conjugates (RDC) Market Share by Country (2020-2031)
 Figure 41. Mexico Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Share by Country (2020-2031)
 Figure 45. Turkey Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. POINT Biopharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 49. Telix Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 50. ITM AG Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 51. Bayer AG Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 52. Novartis Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 53. Lantheus Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 54. Curium Pharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 55. Uihc Pet Imaging Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 56. Grand Pharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 57. BoomRay Pharmaceuticals Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 58. SmartNuclide Biopharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 59. Hengrui Medicine Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 60. Yunnan Baiyao Group Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 61. Sinotau Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 62. Hexin Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 63. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global RDC Radionuclide Drug Conjugate Services Market Research Report 2024
Targeted Radionuclide Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Radiopharmaceutical for Nuclear Medicine Market Research Report 2024
Global Nuclear Radiopharmaceutical Market Insights Forecast to 2030
Radioisotope Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Radiology Drug Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Radiotheranostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Nuclear Medicine Imaging Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oncology Radiopharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Radioactive Isotopes Market Research Report 2025
Radiopharmaceutical Synthesizers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Radioactive Medical Isotopes Market Research Report 2024
Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Research Report 2024
Global Radioisotopes in Industry Market Research Report 2025
Nuclear Medicine Radiopharmaceutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Radioligand Therapy Market Research Report 2025
Isotopes for Nuclear Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Medical Radioactive Isotopes Market Research Report 2025
Rapid Diagnostic Test RDTs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Radiopharmaceutical Solutions Market Research Report 2025

RELATED REPORTS

Global Cephalosporin APIs and Cephalosporin Intermediates Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19G16926
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global ELISA Immunoassay Plates Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-7Z17064
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Ready-to-Use ELISA Kits Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-20P20045
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Moxidectin Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3Z19977
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions